{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-041063","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.305950+00:00","generated_at":"2026-05-22T05:36:12.392540+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nasdaq Panel finds CERo Therapeutics again compliant with $2.5M equity rule","bullets":["On May 7, 2025, Nasdaq Hearings Panel determined CERo complied with Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity).","Compliance achieved through Series D Preferred private placement (4/21/2025), Equity Line drawdown, and public offering in Feb 2025.","CEO Chris Ehrlich says company now focused on lead program CER-1236; anticipates first patient dose in Phase 1 trial soon."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-041063","json":"https://secwatch.observer/filing/0001213900-25-041063.json","markdown":"https://secwatch.observer/filing/0001213900-25-041063.md","text":"https://secwatch.observer/filing/0001213900-25-041063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/0001213900-25-041063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/ea0241411-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:36:12.392540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}